Role of mesenchymal stem cell derived extracellular vesicles in autoimmunity: A systematic review

Abstract

BACKGROUND Mesenchymal stem cells (MSCs) have been reported to possess immune regulatory effects in innate and adaptive immune reactions. MSCs can mediate intercellular communications by releasing extracellular vesicles (EVs), which deliver functional molecules to targeted cells. MSC derived EVs (MSC-EVs) confer altering effects on many immune cells, including T lymphocytes, B lymphocytes, natural killer cells, dendritic cells, and macrophages. A large number of studies have suggested that MSC-EVs participate in regulating autoimmunity related diseases. This characteristic of MSC-EVs makes them be potential biomarkers for the diagnosis and treatment of autoimmunity related diseases. AIM To verify the potential of MSC-EVs for molecular targeted therapy of autoimmunity related diseases. METHODS Literature search was conducted in PubMed to retrieve the articles published between 2010 and 2020 in the English language. The keywords, such as “MSCs,” “EVs,” “exosome,” “autoimmunity,” “tumor immunity,” and “transplantation immunity,” and Boolean operator “AND” and “NOT” coalesced admirably to be used for searching studies on the specific molecular mechanisms of MSC-EVs in many immune cell types and many autoimmunity related diseases. Studies that did not investigate the molecular mechanisms of MSC-EVs in the occurrence and development of autoimmune diseases were excluded. RESULTS A total of 96 articles were chosen for final reference lists. After analyzing those publications, we found that it had been well documented that MSC-EVs have the ability to induce multiple immune cells, like T lymphocytes, B lymphocytes, natural killer cells, dendritic cells, and macrophages, to regulate immune responses in innate immunity and adaptive immunity. Many validated EVs-delivered molecules have been identified as key biomarkers, such as proteins, lipids, and nucleotides. Some EVs-encapsulated functional molecules can serve as promising therapeutic targets particularly for autoimmune disease. CONCLUSION MSC-EVs play an equally important part in the differentiation, activation, and proliferation of immune cells, and they may become potential biomarkers for diagnosis and treatment of autoimmunity related diseases.

Mesenchymal Stem Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus

“…Considering the safety of MSC transplantation, many investigators have focused on EVs derived from MSCs. Compared with MSCs, EVs derived from MSCs exhibited similar immunosuppressive functions in several studies in vitro as cell-free therapy and showed high safety ( 66 , 67 ). However, there is currently no standard and high-efficiency extraction method for EVs, which leads to low production yields and increased heterogeneity of MSC EVs ( 68 ).…”

Challenges and advances in clinical applications of mesenchymal stromal cells

“…The "secretome" of MSCs, including secretory proteins such as growth factors, cytokines, and chemokines and EVs such as microvesicles (MVs; 100-1000 nm diameter) and exosomes (40-150 nm diameter), has been shown to Cord blood Hindlimb ischemia model In vitro/ in vivo (mice) Improved engraftment; increased the number of microvessels and smooth muscle α-actin-positive vessels [172] exhibit many of the therapeutic properties of MSCs. For example, MSC-derived EVs have demonstrated similar or even superior therapeutic capacity for autoimmune diseases and neurodegenerative disorders compared with their parental MSCs [176,177]. They also have better safety profiles due to their better immunocompatibility.…”

News About the Extracellular Vesicles from Mesenchymal Stem Cells: Functions, Therapy and Protection from COVID-19

“…This difference is relevant also because proteins and microRNAs (miRNAs) of such cargos induce different therapeutic effects. In addition, they operate as biomarkers, relevant for the diagnosis and the treatment of autoimmunity-related diseases [ 16 , 17 ].…”